National Registry of Hypertension. Epidemiological Characteristics of Hypertension in Argentina. The RENATA 2 study
pp. 340-346
DOI:
https://doi.org/10.7775/rac.es.v85.i4.11061Keywords:
Blood Pressure - Hypertension - Prevalence - EpidemiologyAbstract
Background: Hypertension is the main risk factor for cardiovascular disease and cardiovascular mortality. As the prevalence of hypertension is increasing, it is necessary to know the updated information in Argentina.
Objective: The aim of this study was to evaluate the prevalence, awareness, treatment and control of hypertension in Argentina.
Methods: A cross-sectional study was conducted including subjects ≥ 18 years from 25 cities in Argentina. The participants were surveyed and blood pressure was measured using validated automated sphygmomanometers.
Results: A total of 5.931 subjects were surveyed. Mean age was 43.5±17.1 years. The prevalence of hypertension was 36.3% (95% CI, 35.1-37.6), was higher in men (43.7% vs. 30.4%; p < 0.0001), and increased with age in both sexes. Among subjects with hypertension, 38.8% were unaware of their condition while 5.7% knew it but were not receiving treatment. In 55.5% of cases, subjects were receiving therapy, and only 24.2% were well controlled, particularly women. In treated subjects, 73.4% were receiving monotherapy and hypertension was controlled in only 43.6%. Patients who adhered to treatment had better blood pressure control than those who did not (46.9% vs. 40.1%; p=0.01).
Conclusions: The prevalence of hypertension in Argentina is 36.3%, in agreement with the reports of the World Health Organization for the region. In 38.8% of cases, participants were unaware of their condition. Half of the subjects with hypertension were receiving drug therapy and only 25% were controlled. Three out of four patients treated were receiving monotherapy. Blood pressure control was associated with better adherence to treatment.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Argentine Journal of Cardiology

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.








